2.135

1.67% 0.035

Kiora Pharmaceuticals Inc (KPRX)

Overview News Price History Financials Discussions Forecast Stock Split

Kiora Pharmaceuticals Inc stock is traded at $2.135, with a volume of 14,315. It is up +1.67% in the last 24 hours and up +5.17% over the past month. Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Previous Close:

$2.10

Open:

$2.08

24h Volume:

14,315

Relative Volume:

0.33

Market Cap:

$7.80M

Revenue:

Net Income/Loss:

$2.81M

P/E Ratio:

-0.1488

EPS:

-14.3497

Net Cash Flow:

$7.14M

1W Performance:

+10.05%

1M Performance:

+5.17%

6M Performance:

-25.09%

1Y Performance:

-45.26%

1-Day Range:

$2.05

$2.12

1-Week Range:

$1.94

$2.12

52-Week Range:

$1.7645

$4.18

Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile

Name

Kiora Pharmaceuticals Inc

Sector

Healthcare (1126)

Industry

Biotechnology (624)

Phone

858-224-9600

Address

169 SAXONY RD., ENCINITAS

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

KPRX's Discussions on Twitter

Compare KPRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KPRX Kiora Pharmaceuticals Inc	2.12	7.72M	0	2.81M	7.14M	-14.35
VRTX Vertex Pharmaceuticals Inc	468.04	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	773.71	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	404.07	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	801.66	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	174.78	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Kiora Pharmaceuticals Inc Stock (KPRX) Latest News

Jan 01, 2026

Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 1.5% Higher – What’s Next? - Defense World

Jan 01, 2026

Dec 26, 2025

Kiora Pharmaceuticals (KPRX) Stock Analysis Report | Financials & Insights - Benzinga Italia

Dec 26, 2025

Dec 22, 2025

Kiora Pharmaceuticals, Inc.Common Stock (Nasdaq:KPRX) Stock Quote - FinancialContent

Dec 22, 2025

Dec 21, 2025

Aug Intraday: What momentum indicators show for CALX stockPortfolio Gains Summary & Fast Gain Stock Tips - moha.gov.vn

Dec 21, 2025

Dec 20, 2025

Will Kiora Pharmaceuticals Inc. stock reach all time highs in 2025Weekly Trade Review & Target Return Focused Stock Picks - Улправда

Dec 20, 2025

Is Kiora Pharmaceuticals Inc. stock a defensive play in 2025Weekly Stock Analysis & Free Risk Controlled Daily Trade Plans - Улправда

Dec 20, 2025

Will Kiora Pharmaceuticals Inc. stock rally after Fed decisionsJuly 2025 EndofMonth & Weekly Return Optimization Plans - Улправда

Dec 20, 2025

Dec 19, 2025

Is Kiora Pharmaceuticals Inc. stock overvalued by current metrics2025 Stock Rankings & Verified Momentum Stock Ideas - Улправда

Dec 19, 2025

How Kiora Pharmaceuticals Inc. stock reacts to bond yields2025 Volatility Report & Safe Entry Trade Reports - DonanımHaber

Dec 19, 2025

Why analysts upgrade Kiora Pharmaceuticals Inc. stockJuly 2025 Action & Free High Accuracy Swing Entry Alerts - Улправда

Dec 19, 2025

Is Kiora Pharmaceuticals Inc. stock supported by strong fundamentalsJuly 2025 Highlights & Daily Market Momentum Tracking - DonanımHaber

Dec 19, 2025

How Kiora Pharmaceuticals Inc. stock benefits from global expansionStock Surge & Free Growth Oriented Trading Recommendations - DonanımHaber

Dec 19, 2025

Dec 18, 2025

Can Kiora Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 Analyst Calls & Safe Entry Trade Signal Reports - Улправда

Dec 18, 2025

Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website - TMX Newsfile

Dec 18, 2025

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - TMX Newsfile

Dec 18, 2025

Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study - TMX Newsfile

Dec 18, 2025

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years - TMX Newsfile

Dec 18, 2025

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million - TMX Newsfile

Dec 18, 2025

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini - TMX Newsfile

Dec 18, 2025

Aug Decliners: Is Kiora Pharmaceuticals Inc. stock a defensive play in 2025Swing Trade & Intraday High Probability Alerts - Улправда

Dec 18, 2025

The Biotech Tug-of-War: Is Kiora Pharmaceuticals Positioned to Ride the 2025 Commodity Wave? - FinancialContent

Dec 18, 2025

Dec 15, 2025

Kiora Pharmaceuticals Earnings Notes - Trefis

Dec 15, 2025

Dec 14, 2025

Aug Rallies: How geopolitical tensions affect Kiora Pharmaceuticals Inc stock2025 Bull vs Bear & Community Consensus Trade Signals - moha.gov.vn

Dec 14, 2025

Dec 13, 2025